General MedicationsSUBCUTANEOUSStandard
PROLIA
DENOSUMAB
Standard Dose
60MG/ML
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary
Approval overview PROLIA is listed in Drugs@FDA under application 125320 (BLA).
Review priority: STANDARD Marketing status: Prescription Active ingredient DENOSUMAB Form and strength INJECTABLE; SUBCUTANEOUS - 60MG/ML Sponsor AMGEN Submission history Latest submission status date: 2025-05-30 00:00:00.
Structured Monograph
Clinical summary
Approval overview PROLIA is listed in Drugs@FDA under application 125320 (BLA). Review priority: STANDARD Marketing status: Prescription Active ingredient DENOSUMAB Form and strength INJECTABLE; SUBCUTANEOUS - 60MG/ML Sponsor AMGEN Submission history Latest submission status date: 2025-05-30 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Prescription
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.